On the reduced delisting risk of ordinary shares of Sangamo Therapeutics, Inc. (SGMO)

The International Trading System Limited (hereinafter – ITS) hereby informs on the reduced delisting risk of ordinary shares of Sangamo Therapeutics, Inc. (ISIN US8006771062, hereinafter – Shares, QI) from The NASDAQ Stock Market LLC (hereinafter - Nasdaq).

Information on delisting risk of ordinary shares by Nasdaq

On March 13, 2024 Sangamo Therapeutics, Inc. (hereinafter – the Company) submitted Annual report Form 10-K to The United States Securities and Exchange Commission (hereinafter - SEC). According to the report, on March 1, 2024, the Company announced that it had received notice from Nasdaq that it was back in compliance with the minimum price listing requirement.

Despite the reduced risk, ITS conducts regular monitoring of the relevant information disclosed by the Company for the purpose of prompt response in case of additional risks. For more details, please, refer to the company’s website.